Moreover, we also found that the high expression levels of CXCL13, FCRLA, MS4A1, and PLA2G2D were positively associated with the better response of melanoma patients treated with anti-PD1 and anti-CTLA4 (Figures 6E–H). This evidence concerns the gene PDCD1 and melanoma.